RGC (Regencell Bioscience Holdings) ROC %: -511.13% (As of Dec. 2025)


RGC Regencell Bioscience Holdings Ltd RGC
33 GF Score
Price $8.56
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings ROC %?

Regencell Bioscience Holdings RGC -21.58% 33 ROC % is -511.13% as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Regencell Bioscience Holdings's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -511.13%.

As of today (2026-06-25), Regencell Bioscience Holdings's WACC % is 12.09%. Regencell Bioscience Holdings's ROC % is -183.53% (calculated using TTM income statement data). Regencell Bioscience Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Regencell Bioscience Holdings  (NAS:RGC) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Regencell Bioscience Holdings's WACC % is 12.09%. Regencell Bioscience Holdings's ROC % is -183.53% (calculated using TTM income statement data). Regencell Bioscience Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Regencell Bioscience Holdings ROC % Related Terms

Regencell Bioscience Holdings ROC % Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings ROC % Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC %
Get a 7-Day Free Trial -38.62 -256.50 -366.47 -519.69 -486.45

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.62 -89.33 -100.62 -82.91 -511.13
RGC
33GF Score
Regencell Bioscience Holdings Ltd RGC
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings ROC % Calculation

Regencell Bioscience Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2025 is calculated as:

ROC % (A: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2024 ) + Invested Capital (A: Jun. 2025 ))/ count )
=-3.77 * ( 1 - 0% )/( (0.384 + 1.166)/ 2 )
=-3.77/0.775
=-486.45 %

where

Invested Capital(A: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.438 - 0.134 - ( 7.961 - max(0, 0.194 - 8.114+7.961))
=0.384

Invested Capital(A: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.756 - 0.351 - ( 4.897 - max(0, 0.664 - 4.903+4.897))
=1.166

Regencell Bioscience Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-10.68 * ( 1 - 0% )/( (1.166 + 3.013)/ 2 )
=-10.68/2.0895
=-511.13 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.756 - 0.351 - ( 4.897 - max(0, 0.664 - 4.903+4.897))
=1.166

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.013 - 0 - ( 0 - max(0, 0 - 2.357+0))
=3.013

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -511.13% mean?
Regencell Bioscience Holdings (RGC) has a ROC % of -511.13% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Regencell Bioscience Holdings and its competitors.
Is Regencell Bioscience Holdings' ROC % too high?
Regencell Bioscience Holdings' current ROC % is -511.13%. Overall, Regencell Bioscience Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' ROC % compare to ELAN and NBIX?
Regencell Bioscience Holdings' ROC % of -511.13% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current ROC % is -511.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current ROC % of -511.13%. The current ROC % is -511.13%. Regencell Bioscience Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current ROC % is -511.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
33GF Score

Get the complete analysis for RGC

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.56
Price